ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression

Yasushi Shintani, Yuri Fukumoto, Nina Chaika, Paul M. Grandgenett, Michael A Hollingsworth, Margaret J. Wheelock, Keith R Johnson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Pancreatic cancer is one of the most aggressive malignant diseases. We recently reported that N-cadherin plays a key role in tumor progression and metastasis in pancreatic cancer. For this study, we sought to determine if an N-cadherin-blocking peptide (ADH-1) could prevent N-cadherin-mediated tumor progression in a mouse model for pancreatic cancer. The effect of ADH-1 on N-cadherin-mediated cell scattering and migration on collagen I was examined using pancreatic cancer cells. We also examined the influence of ADH-1 on cell apoptosis. Furthermore, in vivo animal studies were performed using orthotopic injection of N-cadherin overexpressing BxPC-3 cells with or without ADH-1 treatment. BxPC-3 and Capan-1 cells exhibited increased expression of N-cadherin in response to collagen I. This increase in N-cadherin promoted cell scattering and migration in response to collagen I. ADH-1 prevented these changes, but did not inhibit upregulation of N-cadherin. TUNEL assays and immunoblots for caspase-3 showed that ADH-1 induced apoptosis in a concentration dependent and N-cadherin dependent manner in pancreatic cancer cells. ADH-1 treatment resulted in significant reductions in tumor growth and lung metastasis in a mouse model for pancreatic cancer. The N-cadherin antagonist, ADH-1 has significant antitumor activity against N-cadherin-expressing cells using in vitro assays and in an orthotopic mouse model for pancreatic cancer, raising the possibility that N-cadherin antagonists have therapeutic potential for the treatment of pancreatic cancer in humans.

Original languageEnglish (US)
Pages (from-to)71-77
Number of pages7
JournalInternational Journal of Cancer
Volume122
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Cadherins
Pancreatic Neoplasms
Collagen
Cell Movement
Apoptosis
Neoplasm Metastasis
Neoplasms
In Situ Nick-End Labeling
Therapeutics
Caspase 3
Up-Regulation

Keywords

  • ADH-1
  • N-cadherin
  • N-cadherin antagonist
  • Pancreatic cancer
  • Tumor invasion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. / Shintani, Yasushi; Fukumoto, Yuri; Chaika, Nina; Grandgenett, Paul M.; Hollingsworth, Michael A; Wheelock, Margaret J.; Johnson, Keith R.

In: International Journal of Cancer, Vol. 122, No. 1, 01.01.2008, p. 71-77.

Research output: Contribution to journalArticle

Shintani, Yasushi ; Fukumoto, Yuri ; Chaika, Nina ; Grandgenett, Paul M. ; Hollingsworth, Michael A ; Wheelock, Margaret J. ; Johnson, Keith R. / ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. In: International Journal of Cancer. 2008 ; Vol. 122, No. 1. pp. 71-77.
@article{757bdde72e4c454a83c838fdfa19c425,
title = "ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression",
abstract = "Pancreatic cancer is one of the most aggressive malignant diseases. We recently reported that N-cadherin plays a key role in tumor progression and metastasis in pancreatic cancer. For this study, we sought to determine if an N-cadherin-blocking peptide (ADH-1) could prevent N-cadherin-mediated tumor progression in a mouse model for pancreatic cancer. The effect of ADH-1 on N-cadherin-mediated cell scattering and migration on collagen I was examined using pancreatic cancer cells. We also examined the influence of ADH-1 on cell apoptosis. Furthermore, in vivo animal studies were performed using orthotopic injection of N-cadherin overexpressing BxPC-3 cells with or without ADH-1 treatment. BxPC-3 and Capan-1 cells exhibited increased expression of N-cadherin in response to collagen I. This increase in N-cadherin promoted cell scattering and migration in response to collagen I. ADH-1 prevented these changes, but did not inhibit upregulation of N-cadherin. TUNEL assays and immunoblots for caspase-3 showed that ADH-1 induced apoptosis in a concentration dependent and N-cadherin dependent manner in pancreatic cancer cells. ADH-1 treatment resulted in significant reductions in tumor growth and lung metastasis in a mouse model for pancreatic cancer. The N-cadherin antagonist, ADH-1 has significant antitumor activity against N-cadherin-expressing cells using in vitro assays and in an orthotopic mouse model for pancreatic cancer, raising the possibility that N-cadherin antagonists have therapeutic potential for the treatment of pancreatic cancer in humans.",
keywords = "ADH-1, N-cadherin, N-cadherin antagonist, Pancreatic cancer, Tumor invasion",
author = "Yasushi Shintani and Yuri Fukumoto and Nina Chaika and Grandgenett, {Paul M.} and Hollingsworth, {Michael A} and Wheelock, {Margaret J.} and Johnson, {Keith R}",
year = "2008",
month = "1",
day = "1",
doi = "10.1002/ijc.23027",
language = "English (US)",
volume = "122",
pages = "71--77",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression

AU - Shintani, Yasushi

AU - Fukumoto, Yuri

AU - Chaika, Nina

AU - Grandgenett, Paul M.

AU - Hollingsworth, Michael A

AU - Wheelock, Margaret J.

AU - Johnson, Keith R

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Pancreatic cancer is one of the most aggressive malignant diseases. We recently reported that N-cadherin plays a key role in tumor progression and metastasis in pancreatic cancer. For this study, we sought to determine if an N-cadherin-blocking peptide (ADH-1) could prevent N-cadherin-mediated tumor progression in a mouse model for pancreatic cancer. The effect of ADH-1 on N-cadherin-mediated cell scattering and migration on collagen I was examined using pancreatic cancer cells. We also examined the influence of ADH-1 on cell apoptosis. Furthermore, in vivo animal studies were performed using orthotopic injection of N-cadherin overexpressing BxPC-3 cells with or without ADH-1 treatment. BxPC-3 and Capan-1 cells exhibited increased expression of N-cadherin in response to collagen I. This increase in N-cadherin promoted cell scattering and migration in response to collagen I. ADH-1 prevented these changes, but did not inhibit upregulation of N-cadherin. TUNEL assays and immunoblots for caspase-3 showed that ADH-1 induced apoptosis in a concentration dependent and N-cadherin dependent manner in pancreatic cancer cells. ADH-1 treatment resulted in significant reductions in tumor growth and lung metastasis in a mouse model for pancreatic cancer. The N-cadherin antagonist, ADH-1 has significant antitumor activity against N-cadherin-expressing cells using in vitro assays and in an orthotopic mouse model for pancreatic cancer, raising the possibility that N-cadherin antagonists have therapeutic potential for the treatment of pancreatic cancer in humans.

AB - Pancreatic cancer is one of the most aggressive malignant diseases. We recently reported that N-cadherin plays a key role in tumor progression and metastasis in pancreatic cancer. For this study, we sought to determine if an N-cadherin-blocking peptide (ADH-1) could prevent N-cadherin-mediated tumor progression in a mouse model for pancreatic cancer. The effect of ADH-1 on N-cadherin-mediated cell scattering and migration on collagen I was examined using pancreatic cancer cells. We also examined the influence of ADH-1 on cell apoptosis. Furthermore, in vivo animal studies were performed using orthotopic injection of N-cadherin overexpressing BxPC-3 cells with or without ADH-1 treatment. BxPC-3 and Capan-1 cells exhibited increased expression of N-cadherin in response to collagen I. This increase in N-cadherin promoted cell scattering and migration in response to collagen I. ADH-1 prevented these changes, but did not inhibit upregulation of N-cadherin. TUNEL assays and immunoblots for caspase-3 showed that ADH-1 induced apoptosis in a concentration dependent and N-cadherin dependent manner in pancreatic cancer cells. ADH-1 treatment resulted in significant reductions in tumor growth and lung metastasis in a mouse model for pancreatic cancer. The N-cadherin antagonist, ADH-1 has significant antitumor activity against N-cadherin-expressing cells using in vitro assays and in an orthotopic mouse model for pancreatic cancer, raising the possibility that N-cadherin antagonists have therapeutic potential for the treatment of pancreatic cancer in humans.

KW - ADH-1

KW - N-cadherin

KW - N-cadherin antagonist

KW - Pancreatic cancer

KW - Tumor invasion

UR - http://www.scopus.com/inward/record.url?scp=36749038247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749038247&partnerID=8YFLogxK

U2 - 10.1002/ijc.23027

DO - 10.1002/ijc.23027

M3 - Article

VL - 122

SP - 71

EP - 77

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -